Paper Details

  1. Home
  2. Paper Details

Pharmacokinetics of Cenobamate: Results From Single and Multiple Oral Ascending-Dose Studies in Healthy Subjects.

Author: GreeneStephen A, KaminMarc, VernilletLaurent

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This review summarizes the pharmacokinetics, safety, and tolerability of cenobamate, a newly approved antiepileptic drug, in healthy subjects. The results show that cenobamate is generally well tolerated and has a long terminal half-life, making once-daily dosing possible.
Paper Details　
Original Abstract of the Article :
Cenobamate (YKP3089) is an antiepileptic drug recently approved by the Food and Drug Administration for the treatment of focal (partial-onset) seizures in adults. The objectives of a first-in-human single-ascending-dose study and 3 multiple-ascending-dose studies were to characterize the pharmacokin...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1002/cpdd.769

データ提供：米国国立医学図書館（NLM）

Pharmacokinetics of Cenobamate: Results From Single and Multiple Oral Ascending-Dose Studies in Healthy Subjects

This research delves into the world of [antiepileptic drug development], a field constantly seeking to improve treatment options for individuals with epilepsy. The study focuses on [cenobamate], a novel [antiepileptic drug], exploring its [pharmacokinetic profile] and [safety] in healthy subjects. The researchers conducted [single- and multiple-dose studies] to characterize the [absorption, distribution, metabolism, and excretion] of cenobamate. The results demonstrate that [cenobamate exhibits a favorable pharmacokinetic profile] and [generally well-tolerated] within the tested dose range, suggesting its potential for [effective and safe treatment of epilepsy].

Cenobamate: A New Star in the Antiepileptic Drug Landscape

This study offers encouraging news for individuals with epilepsy. Cenobamate, a novel antiepileptic drug, demonstrates a favorable pharmacokinetic profile and good tolerability, paving the way for further investigation and potential use as a safe and effective treatment option.

A Journey Through the Labyrinth of Epilepsy Treatment: Cenobamate's Potential

The desert is a place of constant change, much like the journey of epilepsy treatment. This study provides a compass for navigating the complexities of this condition, highlighting the potential of cenobamate as a new and potentially effective treatment option.

Dr.Camel's Conclusion

This study demonstrates that cenobamate exhibits a favorable pharmacokinetic profile and is generally well-tolerated in healthy subjects, suggesting its potential for effective and safe treatment of epilepsy. Further research is warranted to evaluate its efficacy and safety in individuals with epilepsy.
Date :
  1. Date Completed 2021-08-12
  2. Date Revised 2021-08-12
Further Info :

Pubmed ID

32087001

DOI: Digital Object Identifier

10.1002/cpdd.769

Related Literature

Article Analysis
・Effects of cenobamate
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.